This inventor holds 1 USPTO granted patent. Top assignee: C4 Therapeutics, Inc.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Manjie Zheng: Innovator in Targeted Protein Degradation
Introduction
Manjie Zheng is a notable inventor based in Watertown, MA (US). He has made significant contributions to the field of targeted protein degradation, particularly through his work on BRD9 protein. His innovative approach aims to address disorders mediated by BRD9, which includes abnormal cellular proliferation.
Latest Patents
Manjie Zheng holds 1 patent for his invention titled "Selected compounds for targeted degradation of BRD9." This patent encompasses selected BRD9 protein degradation compounds and their morphic forms, which are crucial for developing treatments for various disorders.
Career Highlights
Zheng is currently employed at C4 Therapeutics, Inc., where he continues to advance his research in targeted therapies. His work is pivotal in the ongoing efforts to create effective treatments for diseases linked to BRD9.
Collaborations
Throughout his career, Manjie Zheng has collaborated with esteemed colleagues, including Katrina L. Jackson and Ning Yin. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Manjie Zheng's contributions to the field of targeted protein degradation exemplify the impact of innovative research on medical science. His work continues to pave the way for new therapeutic strategies in treating complex disorders.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile